CNTX
Context Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website contexttherapeutics.com
- Employees(FY) 9
- ISIN US21077P1084
Performance
+9.29%
1W
+36.99%
1M
+92.33%
3M
+98.02%
6M
+76.99%
YTD
+266.17%
1Y
Profile
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Technical Analysis of CNTX 2024-05-10
Overview:
In analyzing the technical indicators for CNTX over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.
Trend Analysis:
- Moving Averages (MA): The 5-day Moving Average (MA) has been consistently above the S...
Recent News & Updates
- 2024-05-14 00:00
- 2024-05-08 11:56
- 2024-05-08 04:06
- 2024-05-01 19:31
- 2024-05-01 19:30
- 2024-03-31 19:30
- 2024-03-21 01:53
- 2024-03-20 19:43
- 2023-11-09 03:15
- 2023-10-30 21:00
- 2023-10-24 00:30
- 2023-09-26 21:00
- 2023-08-10 02:19
- 2023-08-09 04:10
- 2023-07-31 19:30
- 2023-06-13 01:34
- 2023-06-02 20:27
- 2023-05-10 04:39
- 2023-04-24 00:01
- 2023-04-17 22:15
- 2023-04-04 00:00
- 2023-04-02 19:30
- 2023-03-22 05:08
- 2023-03-14 19:30
- 2023-02-12 19:52
- 2023-02-10 00:36
- 2023-02-06 23:21
- 2023-02-05 18:30
- 2023-01-30 18:30
- 2023-01-08 18:30
Page 1 of 3
previousnext